Data summary (N = 969)
| Characteristics | Description | |
|---|---|---|
| Tracer type | Radiocolloid | 423 (43.7%) |
| Dye | 662 (68.3%) | |
| ICG | 220 (22.7%) | |
| No. of SLN detected | Mean ± SD | 3.2 ± 2.2 |
| Largest type of metastasis in LN including SLN | Negative | 795 (82.0%) |
| ITC | 31 (3.2%) | |
| MIC | 59 (6.1%) | |
| MAC | 84 (8.7%) | |
| Surgical approach | Open | 575 (59.3%) |
| Robotic | 195 (20.1%) | |
| Laparoscopic | 199 (21.5%) | |
| Tumour histotype | Squamous | 605 (62.4%) |
| Adenocarcinoma | 287 (29.6%) | |
| Adenosquamous | 50 (5.2%) | |
| Neuroendocrine | 18 (1.9%) | |
| Other | 9 (0.9%) | |
| Grade | 1 | 149 (15.4%) |
| 2 | 406 (41.9%) | |
| 3 | 246 (25.4%) | |
| N/A | 168 (17.3%) | |
| LVSI | No | 316 (32.6%) |
| Yes | 351 (36.2%) | |
| N/A | 302 (31.2%) | |
| Maximal pathologic tumour diameter [mm] | Mean ± SD | 20.6 ± 13.7 |
| Median (IQR) | 19 (10; 30) | |
| < 0.5 cm | 73 (7.5%) | |
| 0.5–1.99 cm | 424 (43.8%) | |
| 2–3.99 cm | 376 (38.8%) | |
| ≥ 4 cm | 96 (9.9%) | |
| Adjuvant therapy | 312 (32.2%) | |
| if yes: | radiotherapy | 153 (49.0%) |
| chemoradiotherapy | 136 (43.6%) | |
| chemotherapy | 18 (5.8%) | |
| chemoradiotherapy + chemotherapy | 5 (1.6%) | |
| Recurrence | 117 (12.1%) | |